LM Funding Hooks up with Luxor
LM Funding America, Inc. (NASDAQ:LMFA) shares began Wednesday, as the Bitcoin mining and technology-based specialty finance company today announced a strategic partnership between its US Digital Mining and Hosting Co subsidiary and Luxor Technology Corporation, a leader in Bitcoin mining software services, for the deployment of LuxOS firmware on the Company’s Bitcoin mining fleet.The LuxOS firmware upgrade was completed in early February 2025 and is expected to optimize the Company’s machines, increase efficiency and hashrate, and improve overall system reliability across various operational conditions. LM Funding expects this software upgrade to enhance its Bitcoin mining efficiency by 10-15%, directly resulting in higher profitability and extending machine life.CEO Bruce M. Rodgers stated, "We are very pleased about this partnership as it enhances our hashrate by another 10-15% without any additional hardware investment. This enables us to mine more Bitcoin at higher margins and increase profitability.”Aaron Foster, Director of Business Development at Luxor, added, “This partnership represents a critical step forward in optimizing USDM’s mining operations, maximizing uptime, reducing costs, and ensuring systems operate reliably even in challenging conditions. Together with Luxor, the Company is setting a new standard for mining efficiency, profit maximization and performance.”LXR shares began Wednesday ahead 5.5 cents, or 2.9%, to $1.97.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


